MediciNova Announces Abstract regarding the Mechanism by which MN-001 (tipelukast) Alters Triglyceride Metabolism Accepted for Presentation at the 19th International Symposium on Atherosclerosis (ISA2021)
MediciNova, Inc. (NASDAQ: MNOV) announced the selection of an abstract showcasing MN-001 (tipelukast) at the 19th International Symposium on Atherosclerosis (ISA2021) from October 24-27, 2021. The study reveals that MN-001 inhibits arachidonic acid uptake, thereby reducing triglyceride (TG) synthesis in hepatocytes by down-regulating CD36 expression. Dr. Masatsune Ogura will present the findings online post-conference. Previously, MN-001 demonstrated significant TG reduction in clinical trials, showing potential for treating conditions like NASH. MediciNova continues its focus on developing therapies for inflammatory and fibrotic diseases.
- MN-001 showed a significant reduction in triglyceride levels in previous clinical trials.
- New findings on MN-001's mechanism could bolster its market position.
- Presentation at ISA2021 may increase visibility and interest in MN-001.
- None.
LA JOLLA, Calif., Oct. 21, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced an abstract entitled “MN-001 (tipelukast) reduces triglycerides levels in hepatocytes by down-regulating fatty acid translocase/CD36 expression" has been selected for presentation at the 19th International Symposium on Atherosclerosis (ISA2021) to be held October 24 - 27, 2021 in a hybrid format both online and onsite at the Kyoto International Conference Center in Kyoto, Japan.
This study showed that MN-001 (tipelukast) inhibited the uptake of arachidonic acid into hepatocytes and suppressed the synthesis and accumulation of triglycerides (TG) in hepatocytes. These phenomena, which are consistent with earlier findings, suggested that MN-001 (tipelukast) reduced the synthesis and accumulation of TG in hepatocytes by suppressing the expression of CD36.
MediciNova’s research collaborator, Dr. Masatsune Ogura, Associate Professor at the Department of General Medical Science, Chiba University Graduate School of Medicine, will present the results of the study. Dr. Ogura’s e-presentation with narration will be accessible on the ISA2021 website from October 25 to November 30, 2021.
Kazuko Matsuda, M.D. Ph.D, MPH., Chief Medical Officer, MediciNova, Inc., commented, “It has been observed that MN-001 treatment reduces serum TG levels in multiple previous clinical trials. Particularly, in a Phase 2 clinical trial with hypertriglyceridemia subjects with NASH or NAFLD, MN-001 demonstrated a clinically meaningful and statistically significant reduction in mean serum TG with no safety or tolerability issues. We are very pleased that Dr. Ogura will present new findings regarding the mechanism by which MN-001 alters intracellular triglyceride metabolism.”
About MN-001
MN-001 (tipelukast) is a novel, orally bioavailable, small molecule compound thought to exert its effects through several mechanisms to produce its anti-inflammatory and anti-fibrotic activity in preclinical models, including leukotriene (LT) receptor antagonism, inhibition of phosphodiesterases (PDE) (mainly 3 and 4), and inhibition of 5-lipoxygenase (5-LO). The 5-LO/LT pathway has been postulated as a pathogenic factor in fibrosis development, and MN-001's inhibitory effect on 5-LO and the 5-LO/LT pathway is considered to be a novel approach to treat fibrosis. MN-001 has been shown to down-regulate expression of genes that promote fibrosis including LOXL2, Collagen Type 1 and TIMP-1. MN-001 has also been shown to down-regulate expression of genes that promote inflammation including CCR2 and MCP-1. In addition, histopathological data shows that MN-001 reduces fibrosis in multiple animal models.
About MediciNova
MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova’s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM) and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, patients at risk of developing acute respiratory distress syndrome (ARDS), and substance dependence. MN-001 (tipelukast) was evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and is in preparation for a second Phase 2 trial in nonalcoholic steatohepatitis (NASH). MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.
Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words "believes," "expects," "anticipates," "intends," "estimates," "projects," "can," "could," "may," "will," "would," “considering,” “planning” or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova's operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova's collaborations with third parties, the availability of funds to complete product development plans and MediciNova's ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova's filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2020 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.
INVESTOR CONTACT:
Geoff O'Brien
Vice President
MediciNova, Inc.
info@medicinova.com
FAQ
What is the significance of MN-001's presentation at ISA2021?
What were the results of previous clinical trials for MN-001?
When will the presentation of MN-001's findings be available?
What is the focus of MediciNova's research?
